Radiopharmaceuticals Market Growth, Trends & Opportunities 2025 | DataM Intelligence

Radiopharmaceuticals Market involves radioactive drugs used for diagnosis and treatment of diseases, especially cancer and neurological disorders.

AUSTIN, TX, UNITED STATES, May 23, 2025 /EINPresswire.com/ -- The Global Radiopharmaceuticals Market is growing steadily, thanks to new technologies, a rising need for personalized medicine, and strong investments from leading companies. In 2021, the market was valued at around USD 6.24 million, and it's expected to expand at a healthy rate of 6.2% annually between 2024 and 2031.

> The Radiopharmaceuticals Market is rapidly growing, driven by advances in diagnostic imaging and targeted therapies for cancer and neurological disorders worldwide.
>
> 4.1-mini"
>
> *DataM Intelligence*

Market Overview:

Radiopharmaceuticals, which combine radioactive isotopes with pharmaceutical compounds, are increasingly utilized for both diagnostic and therapeutic purposes. The integration of artificial intelligence (AI) in nuclear medicine is enhancing imaging analysis, leading to earlier and more precise disease detection.

Download Sample Report: https://www.datamintelligence.com/download-sample/radiopharmaceuticals-market

Market Drivers and Opportunities:

Technological Advancements: Innovations such as alpha-emitting radiopharmaceuticals and advanced PET tracers are improving diagnostic accuracy and therapeutic efficacy.

Personalized Medicine: The shift towards precision medicine is increasing demand for radiopharmaceuticals that target specific biomarkers, enabling tailored treatment approaches.

Regulatory Support: Regulatory bodies like the FDA and EMA are actively approving new

radiopharmaceuticals, streamlining clinical development and commercialization processes.

Radiopharmaceuticals Market

Market Segmentation:

By Radioisotope Type:
Technetium-99 (Tec.99)
Fluorine-18 (F18)
Iodine-131
Lutetium-177
Yttrium-90
Gallium-68
Gallium-67
Rubidium-82
Iodine-123
Iodine-125
Indium-111
Other radioisotopes.

By Medical Application:
Cancer treatment and diagnosis (Oncology)
Heart-related conditions (Cardiology)
Digestive system disorders (Gastroenterology)
Hormone-related disorders (Neuroendocrinology)
Brain and nervous system issues (Neurology)
Kidney-related diseases (Nephrology)
Other medical applications.

By Radioisotope Source:
Produced using Cyclotrons
Produced in Nuclear Reactors.

By End User:
Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Cancer Research Institutes.

By Region:
North America
Latin America
Europe

Asia Pacific
Middle East
Africa.

Geographical Market Share:

North America: Dominates the global market with an estimated 41.7% share in 2025, attributed to advanced healthcare infrastructure and the presence of leading industry players.

Asia-Pacific: Projected to witness the fastest growth, driven by rising healthcare expenditure, increasing incidence of target diseases, and technological innovations, particularly in Japan.

Key Industry Players:

Prominent companies in the radiopharmaceuticals market include:

Siemens AG
Positron Corporation
Curium
GE Healthcare
Lantheus Holdings Inc.
Sotera Health LLC
Bayer AG
Eckert & Ziegler
Novartis AG
BWX Technologies Inc

Recent Developments in the USA:
In 2023, Eli Lilly invested $10 million in Ionetix to secure a supply of actinium-225, a critical isotope for developing radiopharmaceutical oncology drugs.

Novartis received approval from the US FDA in January 2024 to begin commercial production of Pluvicto, a radioligand treatment for prostate cancer, at their newly built manufacturing plant in Indianapolis.

Recent Developments in Japan:

In early 2024, Advanced Accelerator Applications (AAA), a subsidiary of Novartis, announced plans to expand its manufacturing capabilities in Japan. The company is constructing a new radioligand therapy (RLT) production facility in Sasayama, Hyogo Prefecture, aiming to enhance the supply of targeted therapies for cancer treatment. This move underscores Japan's commitment to advancing nuclear medicine and addressing the growing demand for precision oncology treatments.

In October 2024, Curium Pharma entered into a strategic partnership with PDRadiopharma Inc., a subsidiary of PeptiDream, to develop and commercialize two promising radiopharmaceutical agents in Japan: 177Lu-PSMA-I&T and 64Cu-PSMA-I&T. These agents target prostate-specific membrane antigen (PSMA) and hold potential for both diagnostic imaging and therapeutic applications in prostate cancer management. This collaboration reflects the growing focus on personalized medicine and the integration of radiopharmaceuticals in targeted cancer therapies.

Stay informed with the latest industry insights-start your subscription now:
https://www.datamintelligence.com/reports-subscription

Conclusion:

The radiopharmaceuticals market is on an upward trajectory, fueled by technological advancements, a shift towards personalized medicine, and strategic investments by key industry players. With North America leading in market share and Asia-Pacific, particularly Japan, showing rapid growth, the global landscape is poised for significant developments in the coming years.

Related Reports:

Biopharmaceuticals Market

Oncolytic Viral Therapy Market

Sai Kiran
DataM Intelligence 4Market Research
+1 877-441-4866
email us here
Visit us on social media:
LinkedIn
X